A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

Recruiting now

Conditions studied: Severe Eosinophilic Asthma

In brief

This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.

Key facts

Study ID: NCT07214753
Run by: AstraZeneca
People needed: 335
Starts: 2025-12-20
Expected to finish: 2028-12-31
Last updated by the study team: 2026-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma.
Benralizumab has been prescribed according to the approved label and local reimbursement criteria
Provision of signed Informed Consent Form (ICF) prior to any study-related activities
Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).

You may not qualify if…

Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment
Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial.
Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC).
Pregnant or lactating women.
patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement.
Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice

Where it is running

Research Site — Modena, Italy (enrolling)
Research Site — Naples, Italy (enrolling)
Research Site — Varese, Tradate, Italy (enrolling)
Research Site — Bari, Italy (enrolling)
Research Site — Palermo, Italy (enrolling)
Research Site — Catanzaro, Italy (enrolling)
Research Site — Teramo, Giulianova, Italy (enrolling)
Research Site — Roma, Italy (enrolling)
Research Site — Bologna, Italy (enrolling)
Research Site — Treviso, Montebelluna, Italy (enrolling)
Research Site — Torino, Italy (enrolling)
Research Site — Milan, Italy (enrolling)
Research Site — Roma, Italy
Research Site — Sassari, Italy
Research Site — Siena, Italy
Research Site — Salerno, Battipaglia, Italy
Research Site — Verona, Italy
Research Site — Padova, Cittadella, Italy
Research Site — Bergamo, Italy
Research Site — Bologna, Italy
Research Site — Brescia, Italy
Research Site — Catania, Italy
Research Site — Florence, Italy
Research Site — Foggia, Italy
Research Site — Messina, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.